CHR. OLESEN PHARMACEUTICALS A/S: Financial statements 2020
CVR: 32090168
Source: annual report 2020, Danish Business Authority
01/10/2019 – 30/09/2020
CHR. OLESEN PHARMACEUTICALS A/S (CVR 32090168) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR 1,026,370 and a net result of EUR 454,764 compared with EUR 474,910 the year before. That is a decrease of 4% compared with the year before. Equity in the 2020 report amounted to EUR 599,172. The solvency ratio was 6.4%. The company had 1 employee in the financial year.
- Gross Profit
- EUR 1,026,370
- Profit/Loss
- EUR 454,764
- Equity
- EUR 599,172
- Total Assets
- EUR 9,413,553
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 1M EUR | 455K EUR | 599K EUR | 1 |
| 2019 | - | 1.1M EUR | 475K EUR | 444K EUR | 1 |
| 2018 | - | 468K EUR | 96K EUR | -31K EUR | 1 |
| 2017 | - | 529K EUR | 128K EUR | -126K EUR | 1 |
| 2016 | - | 395K EUR | 21K EUR | -254K EUR | 1 |
Official annual report
How creditworthy is CHR. OLESEN PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
CHR. OLESEN PHARMACEUTICALS A/S has published its annual report for 2019. Gross profit came to DKK 1,069,171, and the net result was DKK 474,910.
About CHR. OLESEN PHARMACEUTICALS A/S
CHR. OLESEN PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Christian Dam Olesen, Mads Christian Olesen and Phillip Christian Dam Quitzau Olesen. The board consists of Tobias Facklam (chair), Christian Dam Olesen and Fabian von Volkmann. The company is owned by CHR. OLESEN A/S and SVVF UG & Co. KG. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR 1,210,782 and a net result of EUR 237,447 compared with EUR 70,556 the year before. Equity in the 2025 report amounted to EUR 1,744,707.
